Market Place
Sourcing Support
Breyanzi Approved as Relapsed Large B-cell Lymphoma Second-Line Therapy
20 Dec 2022 //
PRESS RELEASE
Cancer center leaders lay bare CAR-T makers` struggles
20 Dec 2022 //
FIERCEPHARMA
Evotec Achieves Progress in Neuroscience Collaboration with BMS
16 Dec 2022 //
ACCESSWIRE
Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on Feb 2, 2023
15 Dec 2022 //
PRESS RELEASE
Horizon CEO Walbert in line for major payday after Amgen sale
15 Dec 2022 //
FIERCEPHARMA
BMS to Report Results for Fourth Quarter 2022 on February 2, 2023
15 Dec 2022 //
BUSINESSWIRE
Abecma`s 3rd-line myeloma data not selected by ASH22
13 Dec 2022 //
FIERCEPHARMA
Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris
13 Dec 2022 //
BIOSPACE
Abecma`s 3rd-line myeloma data not selected by ASH22
12 Dec 2022 //
FIERCEPHARMA
ASH: Bristol bolsters Breyanzi`s case in earlier lymphoma
11 Dec 2022 //
FIERCEPHARMA
Bristol Myers Squibb Announces Dividend Increase
08 Dec 2022 //
BUSINESSWIRE
BMS` Zeposia, AbbVie drugs shake up early IBD market
06 Dec 2022 //
FIERCEPHARMA
Bristol Myers, AbbVie drugs shake up first-line prescribing gastroenterologists
02 Dec 2022 //
ENDPTS
Regeneron`s Libtayo delivers lung cancer win with BMS` Yervoy
02 Dec 2022 //
FIERCEPHARMA
Nimbus posts psoriasis data on rival to Bristol Myers` Sotyktu
30 Nov 2022 //
FIERCEBIOTECH
Bristol Myers scraps uniQure cardiovascular gene therapy pact
30 Nov 2022 //
FIERCEBIOTECH
BMS is knocking on the Supreme Court`s door once again
29 Nov 2022 //
FIERCEPHARMA
Lyvgen and BMS partner for Phase II lung cancer antibody trial
28 Nov 2022 //
CLINICALTRIALSARENA
Lyvgen Announces Phase 2 Clinical Collaboration with BMS to Evaluate LVGN7409
27 Nov 2022 //
PRNEWSWIRE
Bristol Myers reassessing portfolio in wake of IRA—report
21 Nov 2022 //
FIERCEBIOTECH
Bristol Myers Squibb opens 125-acre biologics campus in Dublin
11 Nov 2022 //
PHARMATIMES
PicnicHealth Announces Engagement with Bristol Myers Squibb
10 Nov 2022 //
BUSINESSWIRE
Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
09 Nov 2022 //
BUSINESSWIRE
BMS unit in hot water with FDA over Abraxane production flubs
09 Nov 2022 //
FIERCEPHARMA
Supreme Court rejects BMS bid to revive $1.2B patent fine
08 Nov 2022 //
FIERCEPHARMA
Kura pulls up to $150M from Bristol Myers, VC Hercules loan
03 Nov 2022 //
FIERCEBIOTECH
Alkermes joins Bristol Myers in IL-2 exit with oncology business spinoff
03 Nov 2022 //
FIERCEPHARMA
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio
02 Nov 2022 //
BUSINESSWIRE
Moderna clues in to ‘Jeopardy’; BMS, Gilead build out clinical trial diversity
01 Nov 2022 //
ENDPTS
BMS scores a topline treat in Reblozyl phase 3 study
01 Nov 2022 //
FIERCEPHARMA
Bristol Myers Squibb Announces Positive Topline Results of PIII COMMANDS Trial
31 Oct 2022 //
BUSINESSWIRE
New Zeposia data highlight Covid-19 outcomes of long-term cognitive function
27 Oct 2022 //
PHARMABIZ
BMS xpands cancer survivor campaign with actor & spokesperson Sterling K. Brown
27 Oct 2022 //
ENDPTS
Bristol Myers inks extension to Obsidian cell therapy pact
27 Oct 2022 //
FIERCEBIOTECH
BMS reports 3% decline in total revenues in Q3 2022
27 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
Bristol Myers counters Revlimid generics with 3 new launches
27 Oct 2022 //
FIERCEPHARMA
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
25 Oct 2022 //
BUSINESSWIRE
Bristol Myers Q3 sales fall on Revlimid, forex pressure
25 Oct 2022 //
REUTERS
Data Presented Demonstrate Continuous ZeposiaTreatment Prevents Disease Relapse
24 Oct 2022 //
BUSINESSWIRE
BMS lines up a date with the FDA to expand the footprint of its $13B heart drug
22 Oct 2022 //
ENDPTS
BMS` Opdivo Notches Phase III Win in Advanced Melanoma
21 Oct 2022 //
BIOSPACE
ICER calls out three drugs from BMS and Lilly in report
20 Oct 2022 //
ENDPTS
BMS Presents Data from CheckMate -76K - Opdivo Reduced Risk of Death by 58%
19 Oct 2022 //
BUSINESSWIRE
BMS-backed Immatics touts early data, prompting $110M offering
11 Oct 2022 //
FIERCEBIOTECH
Nektar`s plans to buy PureTech confirmed
08 Oct 2022 //
FIERCEBIOTECH
BMS Announces Change to Conference Call Dial-In Information for Q3 Results
07 Oct 2022 //
BUSINESSWIRE
BMS, ConcertAI ally to promote oncology digital clinical trials
06 Oct 2022 //
FIERCEBIOTECH
SyntheX & BMS Enter Into a Research Collaboration to Develop TPD Therapeutics
05 Oct 2022 //
PRNEWSWIRE
BMS inks 2nd biotech deal in one day, this time with Autolus
05 Oct 2022 //
FIERCEBIOTECH
More former BMS employees sue over COVID-19 vaccine requirement
04 Oct 2022 //
FIERCEPHARMA
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with BMS
04 Oct 2022 //
BUSINESSWIRE
BMS & ConcertAI advance novel oncology accelerated digital trial solution
29 Sep 2022 //
PHARMABIZ
BMS got the 1st TYK2 approval. Frazier’s new biotech Sudo hopes to get many more
28 Sep 2022 //
ENDPTS
Why Bristol Myers Squibb Stock Bounced Higher Today
22 Sep 2022 //
MOTLEY FOOL
Bristol Myers (BMY) Skin Cancer Drug Gets EC`s Approval
19 Sep 2022 //
NASDAQ
AbbVie and BMS unveil 360 total job cuts across three CA sites
17 Sep 2022 //
FIERCEPHARMA
BMS Receives ECA for LAG-3-Blocking Antibody Combination, Opdualag
16 Sep 2022 //
BUSINESSWIRE
BMS snares Opdivo melanoma win in eternal struggle with Keytruda
16 Sep 2022 //
FIERCEPHARMA
